PAVmed Inc. (PAVM) Stock

PAVmed Inc., based in New York, New York, operates as a dynamic medical device company at the forefront of innovation in healthcare technology across the United States. Established in 2014 and originally known as PAXmed Inc., the company rebranded as PAVmed Inc. in April 2015. PAVmed is committed to developing cutting-edge medical devices aimed at addressing critical clinical needs. Among its flagship products are CarpX, a percutaneous device designed for the treatment of carpal tunnel syndrome, and EsoCheck, a revolutionary esophageal cell collection device utilized for early detection of adenocarcinoma and Barrett's Esophagus (BE). Additionally, the company offers EsoGuard, an advanced DNA assay using bisulfite-converted next-generation sequencing technology.

PAVmed's robust product pipeline includes innovative solutions such as EsoCure, an esophageal ablation device targeting dysplastic BE, and PortIO, an implantable intraosseous vascular access device. The company also pioneers NextFlo, a disposable infusion platform, and Veris, a comprehensive cancer healthcare platform integrating remote monitoring and data analytics. Furthermore, PAVmed dewelops NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys noninvasive glucose monitoring systems. These advancements underscore PAVmed's dedication to enhancing patient care through groundbreaking medical technologies.

With a focus on advancing healthcare through innovation and technology, PAVmed Inc. continues to expand its portfolio of transformative medical devices. Through strategic research and development initiatives, collaborations, and a commitment to excellence, PAVmed remains at the forefront of driving significant advancements in medical device solutions, aiming to improve outcomes and quality of life for patients globally.